Therapeutic potential of EVs loaded with CB2 receptor agonist in spinal cord injury via the Nrf2/HO-1 pathway
Our results demonstrated that Exo + AM1241 treatment significantly improved motor function recovery, after SCI by decreasing proinflammatory cytokines, and suppressing astrocyte/microglia (GFAP/Iba1) activation in the injury zone. Additionally, this treatment reduces pro-apoptotic proteins (Bax and caspase 3), increases the levels of the anti-apoptotic protein Bcl-2, enhances antioxidant defenses by boosting SOD and GSH, and lowers oxidative stress markers such as MDA. It also activates the Nuclear factor erythroid-2 (Nrf2) related factor 2 signaling pathway, thereby enhancing tissue protection against damage and cell death.
Authors
- Imran Ibrahim Shaikh (ORCID: https://orcid.org/0000-0002-3083-3025)
- Ramesh Singh Bhandari (ORCID: https://orcid.org/0000-0002-8287-948X)
- Shekhar Singh
- Khawar Ali Shahzad (ORCID: https://orcid.org/0000-0003-3798-5301)
- Chuxiao Shao (ORCID: https://orcid.org/0000-0002-7154-1723)
- Jian Xiao (ORCID: https://orcid.org/0000-0002-6591-3324)
- Zhu Xu (ORCID: https://orcid.org/0000-0002-8057-7111)
- Liming Cheng
Institutions
- Tongji University (CN)
- Wenzhou Medical University (CN)
- Lishui City People's Hospital (CN)
- Shanghai Tenth People's Hospital (CN)
- Tongji Hospital (CN)
Publication Details
- Journal
- Redox Report
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1080/13510002.2024.2420572
- Citations
- 7
- Primary Topic
- Spinal Cord Injury Research
- Type
- article
- Field-Weighted Citation Impact
- 2.97